Insider Selling: CryoPort (NASDAQ:CYRX) Director Sells $115,584.30 in Stock

CryoPort, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam sold 11,570 shares of CryoPort stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total transaction of $115,584.30. Following the sale, the director owned 80,758 shares of the company’s stock, valued at approximately $806,772.42. This represents a 12.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

CryoPort Trading Down 2.5%

Shares of NASDAQ CYRX opened at $9.40 on Monday. CryoPort, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $11.44. The firm has a market capitalization of $470.66 million, a P/E ratio of 8.03 and a beta of 1.51. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. The company’s 50 day simple moving average is $9.43 and its 200 day simple moving average is $8.52.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $44.23 million during the quarter, compared to analysts’ expectations of $41.22 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. On average, analysts predict that CryoPort, Inc. will post -0.99 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CYRX. BTIG Research raised their target price on CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 8th. Needham & Company LLC boosted their price objective on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, UBS Group increased their target price on shares of CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $12.83.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CYRX. The Manufacturers Life Insurance Company increased its stake in shares of CryoPort by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock worth $136,000 after purchasing an additional 1,557 shares during the period. Avanza Fonder AB grew its holdings in CryoPort by 31.4% in the 2nd quarter. Avanza Fonder AB now owns 10,882 shares of the company’s stock valued at $81,000 after buying an additional 2,601 shares in the last quarter. Nisa Investment Advisors LLC increased its position in CryoPort by 299.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock worth $27,000 after buying an additional 2,729 shares during the period. MetLife Investment Management LLC lifted its holdings in shares of CryoPort by 13.8% during the first quarter. MetLife Investment Management LLC now owns 24,641 shares of the company’s stock worth $150,000 after buying an additional 2,980 shares in the last quarter. Finally, State of Wyoming boosted its position in shares of CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock valued at $106,000 after acquiring an additional 3,301 shares during the period. Institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.